Skip to Content
Current OncologyCurrent Oncology
  • Review
  • Open Access

1 August 2018

11 Pages

Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer

,
,
and
1
Department of Oncology, University of Calgary, 1331 29th Street NW, Calgary, AB T2N 4N2, Canada
2
Tom Baker Cancer Centre, Calgary, AB, Canada
3
Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
4
Department of Medical Oncology, Cancer Care Manitoba, Winnipeg, MB, Canada

Abstract

Lung cancer is the leading cause of cancer-specific death among Canadians, with non-small-cell lung cancer (NSCLC) being the most common histologic variant. Despite advances in the understanding of the molecular biology of NSCLC, the survival rate for this malignancy is still poor. It is now understood that, to evade detection and immune clearance, NSCLC tumours overexpress the immunosuppressive checkpoint protein programmed death ligand 1 (PD-L1). Inhibiting the PD-1/PD-L1 axis with monoclonal antibodies has significantly changed the treatment landscape in NSCLC during the last 5 years. Despite evidence of clinical response in some patients, only approximately 20% of patients obtain any durable benefit, and many of the patients who do respond ultimately relapse with drug-resistant disease. The identification of patients who are most likely to benefit from such therapy is therefore important. In the present review, we cover the basics of the PD-1/PD-L1 axis and its clinical significance in NSCLC, biomarkers that are predictive of treatment response, relevant clinical trials of PD-1/PD-L1 blockade completed to date, and proposed mechanisms of acquired therapeutic resistance.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.